Kathryn F Mileham

Dr. Kathryn F Mileham


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HDHerbert L. Duvivier
Herbert L. Duvivier
MRMichael Rothe
Michael Rothe
PMPam K. Mangat
Pam K. Mangat
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
EAEugene R. Ahn
Eugene R. Ahn
RSRichard L. Schilsky
Richard L. Schilsky
#TAPUR results of pembrolizumab in various tumors with HTMB extend KEYNOTE-158 data that led to FDA approval in tumors with HTMB

9 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RHR. Donald Harvey
R. Donald Harvey
KMKathryn F Mileham
Kathryn F Mileham
VBVishal Bhatnagar
Vishal Bhatnagar
JBJamie R. Brewer
Jamie R. Brewer
ARAtiqur Rahman
Atiqur Rahman
TUThomas S. Uldrick
Thomas S. Uldrick
Purpose: Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently and without evidence to justify their use. The authors sought to determine how washout period and concomitant medication allowances can be broadened to speed trial enrollment and improve the generalizability of trial data to a larger oncology practice population without compromising the safety of trial participants. Experimental Design: A multistakeholder working group was convened to define problems associated with excessively long washout periods and exclusion of patients due to concomitant medications. The group performed a literature search and evaluated study data from the Pancreatic Cancer Action Network (PanCAN), Emory University School of Medicine (Atlanta, GA), and the FDA to understand recent approaches to these eligibility criteria. The group convened to develop consensus recommendations for broadened eligibility criteria. Results: The data analysis found that exclusion criteria based on washout periods and concomitant medications are frequently inconsistent and lack scientific rationale. Scientific rationale for appropriate eligibility criteria are presented in the article; for washout periods, rationale is presented by treatment type. Conclusions: Arbitrary or blanket washout and concomitant medication exclusions should be eliminated. Where there is evidence to support them, clinically relevant washout periods and concomitant medication–related eligibility criteria may be included. See related commentary by Giantonio, p. 2369

25 October 2021 in JCO Oncology Practice
Verified
Journal Article
Open access
KMKathryn F Mileham
Kathryn F Mileham
SBSuanna S. Bruinooge
Suanna S. Bruinooge
CACharu Aggarwal
Charu Aggarwal
APAlicia L. Patrick
Alicia L. Patrick
CDChristiana Davis
Christiana Davis
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
PURPOSE: People with cancer are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ASCO's COVID-19 registry promotes systematic data collection across US oncology practices.METHODS: Participating practices enter data on patients with SARS-CoV-2 infection in cancer treatment. In this analysis, we focus on all patients with hematologic or regional or metastatic solid tumor malignancies. Primary outcomes are 30- and 90-day mortality rates and change over time.RESULTS: Thirty-eight practices provided data for 453 patients from April to October 2020. Sixty-two percent had regional or metastatic solid tumors. Median age was 64 years. Forty-three percent were current or previous cigarette users. Patients with B-cell malignancies age 61-70 years had twice mortality risk (hazard ratio = 2.1 [95% CI, 1.3 to 3.3]) and those age > 70 years had 4.5 times mortality risk (95% CI, 1.8 to 11.1) compared with patients age ≤ 60 years. Association between survival and age was not significant in patients with metastatic solid tumors ( P = .12). Tobacco users had 30-day mortality estimate of 21% compared with 11% for never users (log-rank P = .005). Patients diagnosed with SARS-CoV-2 before June 2020 had 30-day mortality rate of 20% (95% CI, 14% to 25%) compared with 13% (8% to 18%) for those diagnosed in or after June 2020 ( P = .08). The 90-day mortality rate for pre-June patients was 28% (21% to 34%) compared with 21% (13% to 28%; P = .20).CONCLUSION: Older patients with B-cell malignancies were at increased risk for death (unlike older patients with metastatic solid tumors), as were all patients with cancer who smoke tobacco. Diagnosis of SARS-CoV-2 later in 2020 was associated with more favorable 30- and 90-day mortality, likely related to more asymptomatic cases and improved clinical management.

1 July 2022 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
CFCarol J. Farhangfar
Carol J. Farhangfar
GSGregory T. Scarola
Gregory T. Scarola
VMVictoria A. Morris
Victoria A. Morris
FFFarhang Farhangfar
Farhang Farhangfar
KDKathryn Dumas
Kathryn Dumas
DRDerek Raghavan
Derek Raghavan
PURPOSE: Clinical trials of novel and targeted agents increasingly require biomarkers for eligibility. Precision oncology continues to evolve, but challenges hamper broad use of molecular profiling (MP) that could increase the number of patients benefiting from targeted therapy. We implemented an integrated clinical genomics program (CGP), including a virtual Molecular Tumor Board (MTB), and examined its impact on MP use and impact on clinical trial accrual in a multisite regional-based cancer system with an emphasis on effects for isolated clinicians. METHODS: We assessed MP and MTB use from 2010 to 2020 by practice location, physician experience, and patient characteristics. Use of MTB-recommended treatments was assessed. Clinical trial enrollment was evaluated for patients with MP versus MP and MTB review. RESULTS: After CGP implementation, the number of physicians using MP and the number of MP tests increased ≥ 10-fold. The proportion of Hispanic patients with MP was the same as that in the system (both 2%) with marginal differences observed in the proportion of African Americans tested compared with the system population (16% v 19%). Physicians followed MTB treatment recommendations in 74% of cases. Rapid clinical decline was the most common reason why physicians did not follow MTB recommendations. Clinical trial accrual was 15% (669 of 4,459) for patients with MP alone and 28% (94 of 334) with both MP and MTB review. Clinical trial availability and patient out-of-pocket costs affected MP use. CONCLUSION: Integrating CGP into clinical workflow with decision support tools, trial matching, and management of patient costs led to increased use of MP by physicians with all levels of experience, enhanced clinical trial accrual, and has the potential to reduce disparities in MP.

27 March 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
MSMargaret R. Smith
Margaret R. Smith
YWYuezhu Wang
Yuezhu Wang
RDRalph D’aGostino
Ralph D’aGostino
YLYin Liu
Yin Liu
JRJimmy Ruiz
Jimmy Ruiz
FXFei Xing
Fei Xing
Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in selecting the most effective therapy for all patients with various genetic backgrounds. To examine whether patients’ mutation profiles are associated with the response to a specific treatment, we collected comprehensive clinical characteristics and sequencing data from 524 patients with stage III and IV NSCLC treated at Atrium Health Wake Forest Baptist. Overall survival based Cox-proportional hazard regression models were applied to identify mutations that were “beneficial” (HR < 1) or “detrimental” (HR > 1) for patients treated with chemotherapy (chemo), immune checkpoint inhibitor (ICI) and chemo+ICI combination therapy (Chemo+ICI) followed by the generation of mutation composite scores (MCS) for each treatment. We also found that MCS is highly treatment specific that MCS derived from one treatment group failed to predict the response in others. Receiver operating characteristics (ROC) analyses showed a superior predictive power of MCS compared to TMB and PD-L1 status for immune therapy-treated patients. Mutation interaction analysis also identified novel co-occurring and mutually exclusive mutations in each treatment group. Our work highlights how patients’ sequencing data facilitates the clinical selection of optimized treatment strategies.

16 March 2022 in Clinical Lung Cancer
Verified
Journal Article
Closed access
DCD Ross Ross Camidge Camidge
D Ross Ross Camidge Camidge
TMTeresa Moran
Teresa Moran
IDIngel Demedts
Ingel Demedts
HGHeidrun Grosch
Heidrun Grosch
KMKathryn F Mileham
Kathryn F Mileham
ESEgbert Smit
Egbert Smit